Net worth tracking
Login Sign Up
  • All Opinions
  • Top Picks
  • Discover
  • Companies
  • Experts
WATCH LIST
Home » Weekly Top Picks

Biotechnology, Gene-editing and Medical Research Stocks to Buy in 2019

Melisa R. H.Melisa R. H. Posted On October 3, 2019
0
1.5K Views
0
0
Shares
  • Share On Facebook
  • Tweet It

The medical space has been a hot sector these past few years, and have widely outperformed the market. These sectors are defensive as they are not tied to an economic cycle. Furthermore, medical, biotech and gene-editing firms will profit from the aging population and growing need for these services and drugs.

Recently, the sector has pulled back due to promises by the US government to lower drug prices and further regulate the sector. However, it seems analysts are still bullish for the sector. The next election cycle will be a key turning point for these stocks.

👩‍⚕️ Biotechnology & Medical Research

Canada Stocks

Resverlogix Corp. (RVX-T)
A clinical biotechnology company that develops epigenetic drugs that treats neurodegenerative diseases, diabetes and other chronic illnesses. They are currently paying down debt.

Resverlogix Corp. (RVX-T) — Stockchase
Resverlogix Corp. (RVX-T) — Stockchase

(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.

stockchase.com stockchase.com

Spectral Med Inc (EDT-T)
A multinational company that specializes in endotoxin activity assay (EAA) diagnostic and therapy services. The EAA diagnostic product is their main revenue driver.

Spectral Med Inc (EDT-T) — Stockchase
Spectral Med Inc (EDT-T) — Stockchase

There is nothing more powerful than a base breakout, and this had one in February of this year. This one is on a trend line right now and there is absolutely nothing wrong with the chart.

stockchase.com stockchase.com

Microbix Biosystems (MBX-T)
A biomedical testing company that saw earnings up 40% last quarter. They are increasing capacity and is trading at a reasonable PE. Robert McWhirter choses it as a top pick in May.

Microbix Biosystems (MBX-T) — Stockchase
Microbix Biosystems (MBX-T) — Stockchase

(A Top Pick May 17/19, Down 7%) He still holds this one. He participated in a financing about four months ago. They produce tests for HPV, but unfortunately COVID-19 has taken center stage. He likes their quality assessment tests and the outlook remains positive.

stockchase.com stockchase.com

Reliq Health Techniques (RHT-X)
A software as a service solution company for remote patient monitoring, telemedicine and collaborative care. The stock experienced a pullback but it is starting to recover due to their long-term potential.

Reliq Health Techniques (RHT-X) — Stockchase
Reliq Health Techniques (RHT-X) — Stockchase

They said they will be cash flow positive moving into 2020. If they have the growth rate they are projecting, then you will see the stock start to move again. Right now it is in the penalty box.

stockchase.com stockchase.com

Neptune Wellness Solutions Inc. (NEPT-T)
A nutrition products company that focuses on unique nutrition solutions with specialty ingredients. They are shifting their focus from krill oil extraction to cannabis oil.

Neptune Wellness Solutions Inc. (NEPT-T) — Stockchase
Neptune Wellness Solutions Inc. (NEPT-T) — Stockchase

Doesn't know this well. They're in the cannabis sector, more in the extraction market, an area that will continue to expand. He's watching their progress in earnings.

stockchase.com stockchase.com

U.S.Stocks

CRISPR Therapeutics AG (CRSP-Q)
A small cap company that develops gene medication. They recently closed a deal with a pharma company that will help scale their products.

CRISPR Therapeutics AG (CRSP-Q) — Stockchase
CRISPR Therapeutics AG (CRSP-Q) — Stockchase

A small company that develops transformative gene medications. They are a small fish in a big sea. A recent transaction with a pharma company allows them to scale out their product, but it is still early. (Analysts’ price target is $58.05)

stockchase.com stockchase.com

Regeneron Pharmaceuticals Inc (REGN-Q)
A biotech company. That has several core products generating good free cash flow. Their partners include Sanofi to treat severe asthma. Paul MacDonald chose it as a Top Pick in July.

Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase
Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase

Buy it under $500. It hasn't been in the news lately. They have a great Covid drug, but aren't making enough of it.

stockchase.com stockchase.com

First Trust Biotechnology Index Fund (FBT-N)
An investment fund that corresponds to the NYSE Arca Biotechnology IndexSM. It tracks the performance of small, mid and large cap companies in the biotech industry.

First Trust Biotechnology Index Fund (FBT-N) — Stockchase
First Trust Biotechnology Index Fund (FBT-N) — Stockchase

(A Top Pick May 8/17. Up 11.02%.) The period of seasonal strength for this is usually early May right through until the middle of July. We have reached the point where seasonality no longer applies. Now is a good time to take the money off the table.

stockchase.com stockchase.com

Gilead Sciences Inc. (GILD-Q)
A pharmaceutical company that produces high priced drugs for hepatitis C and HIV. It trades at less than 9 times earnings with a 4% yield.

Gilead Sciences Inc. (GILD-Q) — Stockchase
Gilead Sciences Inc. (GILD-Q) — Stockchase

They had good news about new drugs recently, but the stock still sold off. That's a sell signal.

stockchase.com stockchase.com

Pharmaceuticals

Pfizer Inc (PFE-N)
An American pharmaceutical corporation that produces a variety of well known drugs. The seasonal weakness is in mid-October. It is currently consolidating and is sure to appreciate in the near future.

Pfizer Inc (PFE-N) — Stockchase
Pfizer Inc (PFE-N) — Stockchase

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

stockchase.com stockchase.com

Biogen IDEC Inc. (BIIB-Q)
A multinational biotechnology company that treats neurodegenerative diseases using innovative techniques. This was dragged down along with the whole sector. They experienced a pullback after they closed an Alzheimer study that caught the market by surprise.

Biogen IDEC Inc. (BIIB-Q) — Stockchase
Biogen IDEC Inc. (BIIB-Q) — Stockchase

Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS…

stockchase.com stockchase.com

Bristol Myers Squibb (BMY-N)
A large cap American pharma company that produces prescription drugs for several therapeutic areas. Their latest drugs haven’t done as well as hoped. They are currently in discussion to merge with CELG-Q.

Bristol Myers Squibb (BMY-N) — Stockchase
Bristol Myers Squibb (BMY-N) — Stockchase

It was up nearly 4% today during JPMorgan's healthcare conference. BMY delivered good news. Management announced strong early revenue goals for new products, including three new drugs that could hit $4 billion in sales this decade. Their strong pipeline of drugs was bulked by buying Celgene and MyoKardia. They also announced a bullish free cash-flow…

stockchase.com stockchase.com

Novartis AG (NVS-N)
One of the largest multinational Swiss pharmaceutical company. They are refocusing on generic drugs and have sold their ophthalmology business.

Novartis AG (NVS-N) — Stockchase
Novartis AG (NVS-N) — Stockchase

A joint pharmaceutical company that has two businesses: branded and generic. The generic side will be very interesting post-covid when countries will be indebted and must provide cost-effective health care. The product pipeline looks reasonable. 6% dividend growth in the past 10 years. A safe steady growth opportunity. (Analysts’ price target is $102.00)

stockchase.com stockchase.com

Amgen Inc. (AMGN-Q)
A biopharmaceutical company that is the world’s largest independent biotech firm. It is considered the preeminent biotech companies with some good drugs. It trades at a 11x earning which is considered reasonable.

Amgen Inc. (AMGN-Q) — Stockchase
Amgen Inc. (AMGN-Q) — Stockchase

Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a…

stockchase.com stockchase.com

Mylan Inc (MYL-Q)
A global generic and specialty pharmaceuticals company. This is the company that produces Epi Pens. Analysts are uncertain since there is a lot of headwinds on pricing and government intervention.

Mylan Inc (MYL-Q) — Stockchase
Mylan Inc (MYL-Q) — Stockchase

TEVA-N vs. MYL-Q. He does not like either at these prices. They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals. The FDA is going to alleviate the delays on getting new drugs to market. He wants to be…

stockchase.com stockchase.com

Eli Lilly & Co. (LLY-N)
A global pharma company that recently made an acquisition in oncology. They recently had one of their popular drugs withdrawn. They outperformed in 2018 Q4 and they have potential blockbuster diabetes and heart disease drugs in the pipeline.

Eli Lilly & Co. (LLY-N) — Stockchase
Eli Lilly & Co. (LLY-N) — Stockchase

He owns a basket. He owns this one for their oncology division. He has not owned it for anything COVID-related. Sometimes it is better to buy a basket of these companies.

stockchase.com stockchase.com

Medical Equipment, Supplies & Distribution

Medtronic Inc (MDT-N)
The maker of the first pacemaker and several other similar devices. They are starting to enter emerging markets such as India and Bangladesh where there is a need for these devices. Michael Decter chose this as a top pick on October 2, 2019.

Medtronic Inc (MDT-N) — Stockchase
Medtronic Inc (MDT-N) — Stockchase

Likes this medical device-maker. They presented at today's JPMorgan's healthcare conference. The stocked slipped 1% today after the company trimmed organic growth forecast this quarter because the explosion of Covid cases is forcing the postponement of medical procedures. This happened at a previous conference, so he's not surprised. The Covid issue is temporary and meanwhile…

stockchase.com stockchase.com

Baxter International Inc (BAX-N)
A Fortune 500 health care company. The dividend is very high though current valuations are quite rich. They are focusing on new product developments that generates good growth.

Baxter International Inc (BAX-N) — Stockchase
Baxter International Inc (BAX-N) — Stockchase

Top healthcare pick. Valuation is rich, though the dividend is decent. He will suggest a better stock in Top Picks.

stockchase.com stockchase.com

Abbott Labs (ABT-N)
A multinational diversified healthcare company. It hasn’t been impacted by the focus on drug pricing. It sells generic dugs to emerging markets. They also have a great track record of dividend increases with a yield of 1.5%

Abbott Labs (ABT-N) — Stockchase
Abbott Labs (ABT-N) — Stockchase

ABT vs. JNJ Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

stockchase.com stockchase.com

Becton Dickinson (BDX-N)
A medtech company that manufactures medical devices, instrument systems and reagents. It is in medical supplies, not drugs, and supplies primarily to hospitals. A product under FDA review has made the price pull back. They have a good record of dividend appreciation and have opportunities ahead. Barry Schwartz chose it as a top pick on June 24, 2019.

Becton Dickinson (BDX-N) — Stockchase
Becton Dickinson (BDX-N) — Stockchase

"Canadian Tire" of healthcare products for clinics and medical offices. Products are one-use only. Elective surgeries have been cancelled, so stock has not done much. Will shine in post-Covid era. Yield is 1.38%. (Analysts’ price target is $272.31)

stockchase.com stockchase.com

Stryker Corp. (SYK-N)
A Fortune 500 medtech firm. They are a leader in robotic surgery and have great organic growth. It is as defensive name since it is not tied to the economic cycle.

Stryker Corp. (SYK-N) — Stockchase
Stryker Corp. (SYK-N) — Stockchase

(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.

stockchase.com stockchase.com

Alpha Pro Tech (APT-A)
A company that has a building supplies business and hospital protection business. Whenever there is a pandemic scare, this company takes off. If there is another scare, this will do well.

Alpha Pro Tech (APT-A) — Stockchase
Alpha Pro Tech (APT-A) — Stockchase

This is funny in terms of a long-term outlook. They have a buildings supplies business, and the hospital protection business. Whenever there is a pandemic in the works, this company takes off. It has been moving around $4 per share, and thinks it could go a fair bit higher. He would like to get $6+…

stockchase.com stockchase.com
Post Views: 1,503
0
Shares
  • Share On Facebook
  • Tweet It




Trending Now
Canadian Tire Corporation Ltd., Royal Bank and More at 52-week Highs (Jan 06-12)
Melisa R. H. January 13, 2021
KB Home, Verizon Communications and 20 Stock Top Picks (Jan 08-14)
Melisa R. H. January 15, 2021
Read Next

Markets half slide, U.S. job numbers Friday

  • We're the Stock Chasers
    Hi! We are the Stock Chasers. We write about investing and finance tools we love. We’re passionate about fintech and we invest almost all our affiliate and advertising revenues into the development of Stockchase and Wealthica. We hope you enjoy the stock ideas and product reviews!
  • Join 39,652 Investors

    Winning in the Market eBook
    We deliver stock ideas to your inbox. Sign up free, get the ebook!

  • Top Reviews

    • The Ugly Truth About Identity Theft – Free Credit Report
      10
    • Questrade Review: Pros & Cons of Trading with Questrade Canada (2021)
      8.5
    • Questrade vs Others | The Review Competitors Don’t Want you to Read (2021)
      7.4
  • Popular Posts

    • Canadian Tire Corporation Ltd., Royal Bank and More at 52-week Highs (Jan 06-12)
    • KB Home, Verizon Communications and 20 Stock Top Picks (Jan 08-14)
    • Richelieu Hardware, Eastmain Resources Inc and More Earnings Reports this Week (Jan 18-22)
    • Questrade vs Others | The Review Competitors Don't Want you to Read (2021)
    • Questrade Review: Pros & Cons of Trading with Questrade Canada (2021)
  • Stock Lists

    • 4 Proven Financial Stocks Riding the Blue Wave
      January 13, 2021
    • Top 8 ETF Stocks To Watch in 2021
      January 8, 2021
    • Top 10 Finance Stocks To Watch in 2021
      January 7, 2021
    • Top 5 Energy Stocks To Watch in 2021
      January 6, 2021
    • Battle of the Stocks: Proven Tech Stocks to Buy in 2021
      December 22, 2020


  • Get $50 in free trades.


  • Stockchase neither recommends nor promotes any investment strategies.

    About us : Privacy & Terms : Contact us

© Stockchase Inc.
Press enter/return to begin your search